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We have investigated the effects of the low-toxic retinoid, all-trans retinoyl b-glucuronide (RAG) alone and in combination with the
phenylacetate (PA) derivative 4-chloro-phenylacetate (4-CPA) on the human neuroblastoma cell line, LA-N-5. In vitro studies
demonstrated that RAG and 4-CPA treatments alone showed differentiation-inducing activity on LA-N-5 cells, with 4-CPA found to
be about three-fold more potent than the PA parent compound in inducing morphologic differentiation and growth inhibition. As
previously reported for retinoic acid (RA) and PA, RAG and 4-CPA were significantly more effective in their antiproliferative effects
on the cells than either agent alone. Pharmacologic studies of 4-CPA in mice demonstrated that blood plasma levels reached peak
concentrations 4h after bolus administration of the compound and showed slow clearance characteristics with an apparent half-life of
4–8h. As opposed to PA, 4-CPA was found to be essentially odourless and readily consumed in drinking water, giving rise to steady-
state blood plasma levels of 4-CPA in the near mM range. Continuous consumption of 4-CPA in this manner for up to 5 months
demonstrated no apparent adverse effects on the mice. Long-term RAG- and/or 4-CPA-treatment of nude mice injected with LA-N-
5 cells demonstrated that both compounds alone exhibit potent antitumour activity. Together, RAG plus 4-CPA was the most
effective treatment for inhibiting established tumour growth. In contrast, 4-CPA alone was equally as effective as the combination for
preventing tumour development. The potent in vivo antitumour effects of 4-CPA could not be accounted for by the known ability of
PA compounds to induce expression of the RA nuclear receptor beta (RARb) suppressor gene. Taken together, these findings
demonstrate the possibility that RAG and/or 4-CPA may serve as effective, less-toxic alternatives to 13-cis RA, which is presently
being utilised for nb therapy.
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Neuroblastoma (nb) is a tumour of the sympathetic peripheral
nervous system, originating in cells derived from the neural crest.
It is the most common extracranial solid tumour in children, and
comprises up to 50% of malignancies among infants (Gale et al,
1982). One characteristic of this disease is the long-recognised
tendency of the tumours in a certain group of patients, designated
clinically as stage 4S, to undergo spontaneous regression, at times
accompanied by cellular differentiation (Evans et al, 1976). This
property has prompted widespread interest in the use of retinoids
as differentiation-inducing agents for the treatment of this disease.
Matthay et al (1999) reported the results of a prospective double-
blind trial in which 13-cis retinoic acid (13-cis RA) was given for 6
months to children with nb following consolidation therapy of
their disease which included surgery, radiotherapy, chemotherapy,
and/or bone-marrow transplantation. The results indicated that
the 3-year event-free survival of patients taking 13-cis RA was
almost double that of the control groups. These findings have now
prompted the use of long-term administration of 13-cis RA in the
setting of minimal residual disease as part of the standard therapy
of nb. Thus, nb has become only the second cancer, after acute
promyelocytic leukaemia (Piazza et al, 2001), to utilise retinoids as
part of its paradigm for first-line therapy.
These encouraging clinical results have engendered a renewed
interest in using retinoids in a safer and more effective manner for
the treatment of nb. The present therapeutic protocol calls for six,
1-month cycles of 13-cis RA administration. Each cycle consists of
14 consecutive days of oral administration followed by 14 days of a
drug-free ‘holiday’ period. The reasons for this drug-free period
every 2 weeks include the severe hypervitaminosis A side effects as
well as the induction of increased RA metabolism that can occur in
children undergoing continuous treatment with 13-cis RA (Ruiz-
Maldonado et al, 1998). Recently, we have demonstrated that long-
term chronic dosing of mice with all-trans retinoyl b-glucuronide
(RAG) is surprisingly lacking in toxicity and systemic adverse side
effects that are usually associated with long-term retinoid therapy
(Sidell et al, 2000). These studies showed that blood plasma
concentrations of RAG in the micromolar ranges were maintained
throughout the 2-month treatment protocol. Surprisingly, the data
indicated that the plasma concentration of all-trans retinoic acid
(RA) as a hydrolysis product of RAG, also did not decrease during
the course of treatment, as opposed to decreased levels seen after
chronic dosing with RA itself (Regazzi et al, 1997). Received 26 February 2003; revised 8 May 2003; accepted 12 May 2003
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retinoid treatment of nb cells, we previously showed that the
phenylalanine metabolite phenylacetate (PA) can both stimulate
the differentiation of nb cells by itself and act synergistically with
RA (Sidell et al, 1995). These experiments suggested that
differentiation in the presence of both agents includes PA-induced
effects that directly impact on the RA differentiation programme
and require only relatively short priming periods, as well as RA-
independent effects of PA which require the continued presence of
this compound. One example of this former activity is illustrated
by the finding that PA can enhance RA induction of nuclear
retinoic acid receptor-b (RARb) in nb cells, a molecular marker
correlated with retinoid sensitivity and favourable prognosis
(Cheung et al, 1998).
Taken together, the lack of adverse side effects seen with
long-term RAG dosing along with the enhanced retinoid res-
ponses that have been demonstrated by nb cells when cotreated
with PA, have prompted us to address the possibility that RAG/PA
therapy might function as a more effective, nontoxic substitute for
13-cis RA in the treatment of nb. Our results demonstrate the
biological activity of RAG on human nb cells, and suggest that the
activity of this retinoid can safely be enhanced by in vivo
combination treatment with the PA derivative 4-chlorophenylace-
tate (4-CPA).
MATERIALS AND METHODS
Chemicals and solvents
All-trans-retinoyl b-glucuronide was synthesised according to
Becker et al (1996). The purity of RAG was determined by HPLC
(Connor and Smit, 1987). Stock solutions of RAG were prepared by
first dissolving it in dimethylsulphoxide to a concentration of
5 10
 2mM and then diluting it in complete medium to the
indicated concentrations. 4-chloro-phenylacetate (4-CPA) was
obtained from Sigma Chemical Co. (St Louis, MO, USA). Stock
solutions were prepared by neutralising 4-chlorophenylacetic acid
with NaOH and adjusting the volume with distilled water to give a
final concentration of the sodium salt of 3 M. All other chemicals
were purchased from Sigma unless otherwise indicated.
Mice
Female athymic nude mice (5–6-week old) of a CD-1 heritage were
obtained from Charles River (Wilmington, MA, USA). The mice
were housed, maintained, and treated in accordance with NIH and
UKCCCR guidelines for animal use and care under the supervision
of Laboratory Animal Resources, Emory University (Workman
et al, 1998). They received ad libitum a standard pellet diet
(Purina, St Louis, MO, USA) and either tap water or during some
treatment protocols tap water containing 4-CPA as described
below. All food and water was sterilised by autoclaving before
consumption.
Cell culture and inoculation
The LA-N-5 human nb cell line was grown in HEPES-buffered
RPMI 1640 medium supplemented with 10% heat-inactivated FBS,
50IUml
 1 penicillin/streptomycin and 1mg amphotericin B
(complete medium). The effects of various treatments on LA-N-5
cell proliferation was assessed by staining of cell protein with
sulphorhodamine (SRB) as described (Han et al, 2001). Cells
were prepared for inoculation by washing, resuspending in
medium, counting with a haemocytometer and subcutaneous
dorsal injection of approximately 10
7 cells in a volume of
0.1ml. Tumour growth was assessed weekly from the time
when a nodule was first palpated. Tumour volumes were
estimated according to the formula V¼0.4ab
2 with a and b
being the perpendicular axes of the tumours and b being
the smaller axis. Since there was some variation in tumour
size when first palpated, growth was expressed as percent of initial
volume.
Acetylcholinesterase
Specific acetylcholinesterase (AChE) activity was measured as a
biochemical index of the relative state of differentiation of treated
and control LA-N-5 cells (Sidell et al, 1984). To measure the AChE
activity, cells were grown in six-well tissue culture plates for 5 days
in the absence or presence of the indicated concentrations of RAG
and/or 4-CPA, washed twice with isotonic saline and harvested by
vigorous shaking of the culture flask. After removal of saline, cells
were frozen at  701C, thawed by adding ice-cold 10mM sodium
phosphate buffer (pH 7.4) containing 0.5% Triton X-100
(1.5ml10
 6 cells) and sonicated for 10s. Acetylcholinesterase
activity in samples of the homogenate was determined photo-
metrically by following the hydrolysis of acetylthiocholine as
previously described (Sidell et al, 1984). Protein concentrations
were determined with a Sigma Bicinchoninic acid protein assay kit
using BSA as the standard. Results, in nmolh
 1mg
 1 protein, are
expressed as means7s.e.m. of four independent experiments, each
carried out in duplicate.
RNA isolation, reverse transcriptase reaction, and
real-time PCR
LAN-5 cells were treated with appropriate compounds for 2–3
days. Total RNA was then prepared by using TRIzol Reagent
(GIBCO, BRL, Rockville, MD, USA). Reverse transcription was
performed using the Perkin Elmer RT–PCR kit with 4mg RNA in a
20ml reaction volume according to the manufacturer’s instruc-
tions. The reaction conditions were: 421C for 1h and 991C for
5min.
For real-time PCR, we used the Qiagen Master Mix kit
and followed the vendor guidelines with some modifications.
A total reaction volume of 25ml contained 12.5ml of Master
Mix, 2mlo f2 5 m M MgCl2, and 0.25mlo f2 5  SyBr Green
(BioWhittaker Molecular Applications, Rockland, ME, USA). For
RARb,5 ml of cDNA was used and 3ml was used for GAPDH
control. Samples were processed using the Cephied Smart Cycler
software (Cephied Systems, Sunnyvale, CA, USA) under the
following conditions: one denaturation cycle of 951C for 30s
followed by 32 amplification cycles of 951C for 10s, 601C for 15s
and 721C for 40s. Primers for amplifications were made by Sigma-
Genosys and the sequences were as follows: GAPDH sense-50-
CCATGGAGAAGGCTGGG-30; GAPDH antisense-50-CAAAGTTGT-
CATGGATGAC-30,( B200bp amplicon); RARb sense-50-
CACTGGCTTGACCATCGC-30; RARb antisense-50-GAGAGGTGG-
CATTGATCC-30,( B500bp amplicon).
Melt curve analysis of each sample was supplemented with
agarose gel electrophoresis of randomly selected samples to
confirm the success of reactions. Fluorescence spectra were
recorded during the annealing phase of the reaction. Second
derivative analysis of the amplification curves was carried out to
arrive at the threshold cycles for each sample. The following
formula was used to arrive at the fold increase RARb mRNA level
for each sample:
2ðC TÞRARB
2ðC TÞGAPDH
¼ fold-increasedRARbexpressioncomparedwith
controlcells
where C is the cycle threshold (CT) for RARb or GAPDH mRNA
detection in control samples, T¼CT for RARb or GAPDH mRNA
detection in treatment samples.
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Groups of mice were treated with RAG and/or 4-CPA or solvent
controls. RAG was administered by daily subcutaneous
(s.c.) injections for the indicated time periods as previously
described (Sidell et al, 2000). For treating with 4-CPA, the
compound was given either by single intragastric administra-
tion (gavage) or admixed in their drinking water at the
concentrations and time periods indicated in the long-term
studies. At the indicated time after RAG and 4-CPA administra-
tion, mice were anaesthetised using Metofane (methoxyflurane,
Mallinckrodt Veterinary, Mundelein, IL, USA). They were then
exsanguinated until they expired by cardiac puncture into
heparinised syringes. The blood was centrifuged for 12min at
1200g at room temperature and the plasma was recovered and
stored at  201C until analysis by gas chromatogrophy/mass
spatrosopy (GC/MS). Plasma (500–600ml) was obtained from each
mouse.
Extraction and analysis of 4-CPA from plasma samples Quantita-
tion of 4-CPA was performed by GC/MS following ethylacetate/
ether extraction of plasma deproteinised with 7% perchloric
acid, according to standard procedures (Thompson and Markey,
1975; Tanaka et al, 1980). Specifically, 250ml of plasma was
admixed with 250ml of 7% perchloric acid. The mixture was
centrifuged and the supernatant used for the analysis. The
quantitation was accomplished by selective ion monitoring (SIM)
using an external calibration curve obtained with a standard
undergoing the same extracting procedure as the samples.
Corrections for variations in the injections were made with
an internal standard. The response was linear over a wide range
(0–1700nmol).
RESULTS
Morphologic differentiation
We utilised the PA derivative 4-CPA in the present study
because of its documented greater potency in terms of its
differentiation-inducing activity in comparison with the parent
compound (Pineau et al, 1996) and because of its ease in
treating animals in vivo (see below). As shown in Figure 1, 4-
CPA induced neurite outgrowth from LA-N-5 cells. The
temporal aspect of this effect was similar to that reported for PA
(Sidell et al, 1995); it first became apparent after about 3 days of
continuous exposure in culture. In contrast, while maximal
increases in the formation of neurites occurred at PA concentra-
tions between 5 and 10mM, 4-CPA was found to be about three-
fold more potent with maximal neurite-inducing activity occurring
at about 3mM.
As previously reported (Sidell et al, 2000), RAG also induced
neurite sprouting from LA-N-5 cells, with maximal effects
seen at RAG concentrations in the 5–10mM range after
extended periods (46 days). These morphologic changes are
similar to those extensively reported after RA treatment of
LA-N-5 cells (Sidell et al, 1983; Robson and Sidell, 1985), with
the exception that maximal neurite outgrowth is seen with
RA at somewhat lower concentrations (41mM). In the presence
of optimal concentrations of both agents, morphologic differentia-
tion of LA-N-5 was noticeably enhanced; treatment with 3mM
4-CPA plus 5mM RAG resulted in extensive neurite outgrowth
which, after longer periods (approx. 2 weeks), formed an
elaborate network of neurite bundles and thin fibres similar
to that observed with combination RA and PA treatment (Sidell
et al, 1995).
Figure 1 Morphology of LA-N-5 nb cells in the absence and presence of 4-CPA and/or RAG. Cultures were treated for 7 days with vehicle (A), 5mM
RAG (B), 3mM 4-CPA (C)o r3m M 4-CPAþ5mM RAG (D). Cells were plated at different densities (10
5 to 5 10
5 cells in 25cm
2 tissue culture flasks) to
allow for the profound antiproliferative effect of combination treatment. Photographed under phase contrast ( 200).
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Previous studies have demonstrated the antiproliferative effects of
RAG on LA-N-5 cells and indicated that this retinoid was 5–10-
fold less potent than RA on a concentration-dependent basis
(Sidell et al, 2000). Figure 2 shows the dose-dependent effects of 4-
CPA on the growth of LA-N-5 cells as assessed by SRB protein
staining. As seen, 50% growth inhibition was achieved at
approximately 3mM in these 5-day cultures, while little effect
was found at 0.75mM and below. For comparison, the growth
inhibitory effects of PA were also tested in parallel cultures. The
dose-dependent curves indicate that 4-CPA was about three-fold
more potent than PA in inhibiting the growth of LA-N-5 cells. This
greater potency of 4-CPA vs PA was consistent with our
morphologic observations of the relative ability of the two
compounds to induce neurite outgrowth.
As previously reported for RA and PA, RAG and 4-CPA together
were significantly more effective in their antiproliferative effects on
LA-N-5 cells than one would expect from the combined action of
two antiproliferative agents acting through independent mechan-
isms. For example, in Figure 3, cell growth in the presence of 3mM
4-CPA was around 50% of control, while that with 1mM RAG was
82%. Both agents together at these concentrations reduced cell
growth to 30% of control, while 41% would be expected from the
two agents acting independent of each other (0.82 0.50¼41%).
Acetylcholinesterase activity
Concomitant with growth inhibition and neurite outgrowth, we
have shown that AChE activity increases in LA-N-5 cells induced
to differentiate with a variety of agents including RA and PA
(Wuarin et al, 1991; Sidell et al, 1995). As a biochemical marker of
LA-N-5 differentiation, we measured AChE activity in LA-N-5 cells
treated with RAG and 4-CPA for 5 days. In preliminary
experiments, we determined that AChE showed maximal increases
when treated with either agent alone at RAG and 4-CPA
concentrations of 5mM and 3mM, respectively (data not shown).
Previous work with RA and PA demonstrated maximal effects on
AChE activity at concentrations of approximately 1mM and 5mM,
respectively (Sidell et al, 1995). Thus, the differences in the
potency of 4-CPA vs PA and RAG vs RA to increase AChE was
similar to that seen for their comparative effects on morphologic
differentiation (neurite outgrowth) and growth of the cells. As seen
in Figure 4, there was a significant increase in specific AChE
activity in cultures treated with a combination of 4-CPA and RAG
compared with those treated with either agent alone. As previously
reported, the induced increase in AChE activity generally
paralleled the extent and complexity of neurite formation in the
LA-N-5 cultures (Sidell et al, 1984, 1995; Wuarin et al, 1991).
In vivo administration of 4-CPA
The mean concentrations of 4-CPA found in mouse plasma at
various times during a 24h-period after bolus administration of
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Figure 2 Dose–response curves showing antiproliferative effects of 4-
CPA (O) in comparison to PA (K) on LA-N-5 cells as assessed by SRB
protein staining after 5 days of treatment. Values are the averages (7s.e.m.)
of at least three independent experiments for each treatment condition
and are expressed as percent of control cultures as assessed by the SRB
protein assay.
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Figure 3 4-chloro-ph enylacetae and RAG are synergistic in inhibiting
the growth of LA-N-5 cells. Cells were cultured in the presence of 4-CPA
(3mM), RAG (1mM), 4-CPA (3mM)þRAG (1mM), or in the absence of
added compounds as indicated. After 5 days, relative proliferation of the
cultures was assessed by SRB protein staining. Columns represent the mean
(7s.e.m.) of four independent experiments and are expressed as percent
of control cultures as assessed by the SRB protein assay. * Indicates a
significant difference between the single treatment as compared to the
control. ** Indicates significance between combination treatment and
treatments with either 4-CPA or RAG alone. Student’s t-test (two-tailed)
was used for all statistical determinations, where a level of Po0.05 was
considered statistically significant.
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Figure 4 Effects of RAG and 4-CPA on AChE activity in LA-N-5 cells.
Cells were cultured for 5 days in the presence of 5mM RAG, 3mM 4-CPA,
5mM RAGþ3m M 4-CPA, or solvent control as indicated. Bars represent
the mean7s.e.m. of four independent experiments. * Indicates a significant
difference between the single treatment as compared to the control. **
Indicates significance between combination treatment and treatments with
either 4-CPA or RAG alone (Po0.05).
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sthe compound (25.5mg mouse
 1) are shown in Figure 5. We found
the lower limit of detection of 4-CPA to be around 4mgml
 1 by the
GC/MS procedure utilised. As shown, 4-CPA reached peak plasma
concentrations 4h after administration, achieving levels of 3.1mM.
4-chloro-phenylacetate could not be detected in the plasma of any
control (untreated) mouse. As previously determined with PA
(Thibault et al, 1994), clearance of 4-CPA was relatively slow with
an apparent half-life of 4–8h. Even 24h after dosing, plasma levels
of 4-CPA4500mM was still detected.
As opposed to PA, 4-CPA is essentially odourless and readily
consumed in drinking water. As such, admixing in drinking water
provided a convenient method for chronic administration of 4-
CPA for the long periods that may be required due to the long lag
periods necessary for growth of LA-N-5 and other nb tumours in
nude mice (Abemayor et al, 1990). Preliminary studies indicated
that continuous consumption of up to 6mgml
 1 4-CPA in
drinking water for up to 5 months showed no apparent adverse
effects on the mice; there were no significant differences between
4-CPA-consuming and control groups in their water consumption,
growth rate, social behaviour, or vitality. Higher doses of 4-CPA
did show some toxicity in that the growth rate of the 4-CPA-
consuming animals was reduced. Therefore, 6mgml
 1 4-CPA in
drinking water was used in all our in vivo studies. Plasma was
obtained by cardiac puncture from two groups of mice (3 mice
group
 1) that consumed either 6 (HD; high dose) or 3mgml
 1
(LD; low dose) 4-CPA in their drinking water for 24 days. Analysis
by GC/MS indicated that the mean (7s.e.m.) plasma concentration
of 4-CPA in the HD and LD groups were (in mM) 775 (7131) and
194 (736), respectively. Plasma samples obtained from HD-
treated mice at various other times up to 56 days of continuous 4-
CPA consumption showed plasma levels of 4-CPA similar to those
indicated above.
Activation of RARb as an indicator of LA-N-5 response by
pharmacologic concentrations of compounds
In human nb, as in many other tissues, RARb shows low
constitutive expression in untreated cells but is rapidly induced
by retinoic acid (Wuarin et al, 1994). Previous studies by us (Sidell
et al, 1998) and others (Cheung et al, 1998) have demonstrated that
induction of RARb plays a necessary role in the differentiation
response of nb cells to retinoids. Furthermore, the data suggest
that the magnitude of this induction can provide a molecular
marker of the extent of the response. As such, we were interested
in determining the effects on RARb expression of retinoids and 4-
CPA at concentrations measured in the mice blood plasma during
our treatment. For these experiments, real-time RT–PCR was used
to determine relative mRNA levels of RARb in LA-N-5 cells treated
for 2 days with RA, RAG, and 4-CPA at concentrations that were
determined to be achieved in mouse blood plasma following
chronic administration of RAG and 4-CPA as shown in our past
(Sidell et al, 2000) and present work. To this end, our previous
study showed that mean peak plasma levels of retinoids achieved
during long-term daily administration of RAG by s.c. injection
were approximately 0.5mM RA (as a hydrolysis product of RAG)
and 7.5mM RAG. Thus, the treatment concentrations of RA, RAG,
and 4-CPA utilised were 0.5mM, 7.5mM, and 0.75mM, respectively.
As can be seen in Figure 6, RA or RAG alone induced a 3–5-fold
increase in RARb expression compared to controls. Together,
these retinoids were essentially additive and caused about a seven-
fold induction. 4-chloro-phenylacetate alone had no apparent
effect on RARb mRNA levels, and did not affect induction when
combined with either RAG (date not shown) or when added along
with both RAG and RA.
Effects of in vivo treatments on LA-N-5 growth
To determine the effects of treatments on tumour development,
4-CPA (6mgml
 1 in drinking water) and/or RAG (25mmolkg
 1
body weight) treatments were begun 3 days before tumour cell
injections and then continued daily for 30 days after injection of
nb cells (protocol A). Control animals were treated in a similar
fashion except for the administration of solvents in place of RAG
and/or 4-CPA. As previously seen with RAG (Sidell et al, 2000) or
CPA alone (this report), no adverse effects were observed in any of
the treatment groups. As seen in Figure 7, in solvent-treated
controls, 89% (eight out of nine) developed tumours by 120 days
after injection. In contrast, only 33% (three out of nine) of the
animals in the RAG-treated group developed tumours while 20%
(two out of 10) and 10% (one out of 10) showed tumour
development in the 4-CPAþRAG and 4-CPA groups, respectively.
For tumours that did develop, there were no differences between
the groups in terms of average tumour sizes (data not shown).
To assess whether in vivo treatment could affect the growth of
established tumours, groups of animals were treated for 28 days
with solvent or 4-CPA/RAG as mentioned above immediately
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Figure 5 Plasma concentration of 4-CPA following a single gastric
administration of 25.5mg. Data represent the mean of two mice at each
time point.
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Figure 6 Effects of pharmacologic concentrations of 4-CPA and
retinoids on RARb expression. LA-N-5 cells were treated with RA
(0.5mM), RAG (7.5mM), 4-CPA (0.75mM), RA (0.5mM)þRAG (7.5mM), RA
(0.5mM)þRAG (7.5mM)þ4-CPA (0.75mM), or solvent control as
indicated for 2 days. Fold-increased RARb mRNA levels were quantified
by real-time RT–PCR as described in Materials and Methods. Columns
represent the mean (7s.e.m.) of three experiments.
Antitumour effects of RAG and 4-CPA on nb cells
N Sidell et al
416
British Journal of Cancer (2003) 89(2), 412–419 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sfollowing the development of palpable tumours (3–6mm dia-
meters) (protocol B). During this time period, it was found that
while tumours grew progressively in the control group, there was a
diminished growth rate of tumours in animals in the treatment
groups; from week 2 onwards, tumour growth in all the treatment
groups was significantly reduced from that in the control group
(Figure 8). After the full 4-week treatment period, tumours in the
4-CPAþRAG group were significantly smaller than those in the
other animals (Po0.05).
DISCUSSION
The data presented in this report demonstrate the ability of an
easily administered, nontoxic retinoid, RAG, to inhibit nb tumour
development in vivo. In our previous work, we investigated both
the pharmacokinetics of RAG during chronic s.c. administration
and its conversion to RA (Sidell et al, 2000). We have chosen this
route of administration for a number of reasons: (i) RAG was
found to be poorly absorbed from the gastrointestinal track
following oral dosing (Barua, 1997); (ii) elimination of RAG
following s.c. injection has been shown to be relatively slow,
showing a half-life of greater than 10h (Nau et al, 1996; Sidell et al,
2000); (iii) s.c. injection would be a simple, nontraumatic means of
chronic daily treatment of infants with nb as well as a convenient
means of long-term dosing in animal models (vs oral or
intravenous routes). Previous results indicated that the peak
(2h) plasma levels of both RAG and its hydolysis product RA were
similar at all times throughout the entire dosing period (up to 2
months) and showed RAG and RA plasma levels of around 7.0 and
0.5mM, respectively. Thus, in contrast to what occurs during
administration of RA itself (Regazzi et al, 1997), it appeared that
the production of RA from the continuous hydrolysis of persistent
RAG levels did not result in the induction of cytochrome P450
oxidative enzymes. Finally, the studies demonstrated that retinol
levels did not change significantly during the course of RAG
treatment as opposed to that reported with the long-term
administration of some other retinoids such as RA and 13-cis
RA (Barua et al, 1997; Keilson et al, 1979).
Since PA can markedly enhance the differentiation-inducing
effects of retinoids on nb cells in vitro, we were interested in
determining if the antitumour activity of this combination of
agents also extended to nb growth and/or tumour development in
vivo. For these studies, we utilised the PA derivative 4-CPA. It was
previously reported that halogen substitution on the aromatic ring
of PA para to the alkylcarboxyl group can increase the potency by
several fold in terms of its antiproliferative activity on several types
of tumours (Hudgins et al, 1995). Among the derivatives found to
be more potent than the parent compound, 4-CPA inhibited the
growth of prostate carcinoma, glioblastoma, and melanoma with a
potency 3–4 times that of PA. Our in vitro data demonstrated that
this enhanced activity of 4-CPA over that of PA extends to nb cells.
Moreover, we have found that 4-CPA lacks the adverse odour often
associated with PA, and is therefore much more easily adminis-
tered to mice orally admixed with drinking water. As such, we
utilised this convenient method for chronic adminstration of 4-
CPA to mice for relatively long periods of time. In initial
experiments to explore the feasibility of using this method for
achieving therapeutic blood levels in vivo, we determined that
continuous consumption of up to 6mgml
 1 4-CPA in drinking
water for 5 months showed no apparent adverse effects on the
mice. Longer time periods were not tested. Using this methodol-
ogy, steady-state plasma levels of over 750mM 4-CPA were
achieved. This concentration compares favourably with plasma
concentrations of 500–1000mM PA that can be achieved in humans
and rodents by administering either PA itself or its prodrug
phenylbutyrate (PB) by a variety of procedures (e.g., continuous
infusion, injection, oral) (Thibault et al, 1994; Jung, 2001). As with
4-CPA, these concentrations of PA or PB have shown no adverse
side effects in mice (Prasanna et al, 1995). In humans, the only side
effects reported during therapeutic treatments with PA derivatives
have been nausea and somnolence (Batshaw and Monahan, 1987).
In our studies, there were no significant differences in weight
gain, water consumption, social behaviour, or apparent vitality
between any of the treatment and control groups. In the groups
where RAG was part of the treatment paradigm, there were no
observable clinical manifestations of retinoid toxicity such as
alopecia and scaly skin (Teelmann et al, 1993). Since our previous
(Sidell et al, 2000) and present pharmacokinetic studies of RAG
and 4-CPA indicated that biologically active blood levels of RAG,
RA, and 4-CPA can be maintained during chronic long-term
administration of the compounds, we assessed whether such
levels could have therapeutic significance in terms of reduced in
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Figure 7 Development of tumours in in vivo-treated nude mice. Groups
of animals containing nine or 10 mice were treated with 4-CPA (.), RAG
(K), 4-CPAþRAG (m) or solvent controls (J) for 5 days before and 30
days after injection of 0.1ml of 10
7 LA-N-5 nb cells. Tumour development
was recorded on the day that a nodule could first be definitively detected
(B3–5mm diameter).
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Figure 8 Growth of established tumours in in vivo-treated nude mice.
Groups of animals were treated daily with either 4-CPA (.), RAG (K),
4-CPAþRAG (m), or solvent controls (J) for 28 days immediately
following the development of palpable tumours. Tumour growth and
volume were assessed weekly as described in Materials and Methods.
Results represent mean (7s.e.m.) of six to eight animals/treatment group.
On weeks 2 and 3, tumour size in all treatment groups was significantly
reduced in comparison to that of controls only (Po0.05). On week 4,
there was a significant difference in tumour size between any group of
animals in comparison to any other treatment group (Po0.05).
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svivo tumour growth. For these experiments, two in vivo treatment
protocols were utilised; the first where treatment was begun
3 days before tumour injection and continued for 30 days after
injection (protocol A), and the second where treatment was
administered for 28 days starting immediately after the appearance
of palpable tumours (protocol B). As such, protocol A was
designed as a model to evaluate the ability to affect the clinical
remission time and subsequent regrowth of metastatic lesions in
patients following consolidation therapy such as the setting in
which 13-cis RA is now used. On the other hand, protocol B
may be considered a model for testing the potential efficacy on
established, primary nb tumour growth. Previous trials of 13-cis
RA as well as other retinoids on progressive tumour growth in nb
patients have demonstrated little, if any, efficacy (Reynolds and
Lemons, 2001).
Our data showed that the proliferative capacity of the LA-N-5 nb
cells was inhibited by all the in vivo treatments compared to
controls. Of the two protocols used, protocol A in which treatment
was started before tumour cell injection appeared to be the most
effective in increasing the proportion of tumour-free animals.
These results suggest that the treatments may be very effective in
the setting of minimal residual disease or prevention of metastasis.
Recent developments of metastatic mouse models of nb involving
orthotopic implantation of tumour cells (Moats et al, 2000; Khanna
et al, 2002) should provide a powerful tool for testing this
hypothesis. In the presence of established tumours (protocol B),
the treatments also inhibited tumour growth, although we could
not demonstrate a concomitant increase in morphologic or
biochemical differentiation of the nb cells (data not shown). These
findings indicated that RAG alone was at least as effective as that
previouly demonstrated with RA in an identical in vivo nude
mouse model (Abemayor et al, 1990). Although combination RAG
plus 4-CPA was shown to be the most effective treatment for
inhibiting established tumour growth, this combination treatment
was not more effective for preventing tumour development. Thus,
only one out of 10 mice developed a tumour when being treated
with 4-CPA alone. Although 4-CPA has previously not been tested
in vivo, treatment of mice with only its parent compound PA in
conjunction with MCF-7 breast cancer cell inoculation was likewise
shown to be remarkedly effective in preventing tumour develop-
ment (Di Benedetto et al, 2002).
We have demonstrated that PA can enhance RA induction of
RARb in human nb cells, an event which has been implicated as
being necessary for RA-mediated growth inhibiton and differ-
entiation of this cell type (Sidell et al, 1998). These in vitro findings
were supported by Cheung et al (1998), who found strong
correlations between favourable nb patient prognosis and RARb
expression, and that high-level expression of this receptor can
profoundly inhibit nb cell growth even in the absence of exogenous
retinoid. Therefore, we were interested in determining whether the
inhibitory effects of the different treatments correlated with RARb
expression at retinoid and 4-CPA concentrations that were
achieved in vivo. Quantitation of RARb mRNA levels by real-time
PCR suggests that this was not the case. Indeed, 4-CPA alone was
found to be a potent inhibitor of tumour development and growth,
but did not enhance RARb expression compared to controls at
4-CPA blood concentrations that were achieved in vivo. Further-
more, treatment of LA-N-5 cells with concentrations of 4-CPA that
showed maximal growth inhibitory effects in vitro (3mM), only
modestly (otwo-fold) enhanced RARb mRNA levels as compared
to controls (data not shown). A similar small increase of RARb
mRNA levels was also seen following treatment with concentra-
tions of PA that showed marked antiproliferative activity (Sidell
et al, 1995, 1998). Thus, although it is possible that plasma
concentrations of 4-CPA did not accurately reflect tumour tissue
levels of the compound, it is clear that its potent antitumour effects
are not mediated through enhanced RARb signalling. Previous in
vitro findings have revealed retinoid-independent effects of PA
derivatives such as inhibition of protein prenylation, histone
deacetylation activity, and activation of peroxisome-proliferator
activated receptors (Hudgins et al, 1995; Pineau et al, 1996; Jung,
2001). Whether these activities play a role in the in vivo
antitumour activity of 4-CPA is presently unknown. In light of
the recent results demonstrating the effectiveness of retinoids in
preventing nb recurrences in children (Matthay et al, 1999), our
results offer encouragement that RAG and/or PA compounds may
serve as effective, less-toxic alternatives to 13-cis RA therapy,
which is now being utilised in the clinic.
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